New data reveals sugemalimab significantly enhances survival rates in metastatic non–small cell lung cancer, establishing it as a key first-line treatment option.

An expert discusses the advances in managing CAR T-cell therapy toxicities, emphasizing aggressive early treatment of acute complications, the importance of coordinated long-term monitoring with ...

An expert discusses the emerging role of bispecific antibodies in lymphoma treatment, highlighting their expanding use across treatment lines—including as alternatives or bridges to CAR T-cell therapy ...

An expert discusses the evolving landscape of large B-cell lymphoma (LBCL) treatment, highlighting emerging CAR T-cell targets and bispecific antibody strategies, the potential shift toward more ...

The NCCN added critical guidance on Lambert-Eaton myasthenic syndrome to its recommendation for the diagnosis and treatment ...

Medical practices face staffing shortages and rising costs, prompting innovative strategies for health benefits to enhance ...